Financials data is unavailable for this security.
View more
Year on year Elite Pharmaceuticals Inc grew revenues 65.79% from 34.16m to 56.63m while net income improved 464.56% from 3.56m to 20.11m.
Gross margin | 45.27% |
---|---|
Net profit margin | 29.47% |
Operating margin | 22.29% |
Return on assets | 29.15% |
---|---|
Return on equity | 44.32% |
Return on investment | 36.18% |
More ▼
Cash flow in USDView more
In 2024, cash reserves at Elite Pharmaceuticals Inc fell by 705.59k. Cash Flow from Financing totalled 3.39m or 5.98% of revenues. In addition the company used 3.28m for operations while cash used for investing totalled 809.65k.
Cash flow per share | 0.0203 |
---|---|
Price/Cash flow per share | 19.73 |
Book value per share | 0.0545 |
---|---|
Tangible book value per share | 0.0478 |
More ▼
Balance sheet in USDView more
Current ratio | 3.08 |
---|---|
Quick ratio | 2.09 |
Total debt/total equity | 0.1613 |
---|---|
Total debt/total capital | 0.1389 |
More ▼